Clinical Trial Update: Vandetanib and Sirolimus in Patients With Recurrent Glioblastoma [Phase 1]

View source ↗

Summary

Phase 1 study evaluating vandetanib in combination with sirolimus for recurrent glioblastoma has completed enrollment.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma

Drugs mentioned

• Sirolimus (Sirolimus)
• Vandetanib (vandetanib)

Snippet

Sponsor: Massachusetts General Hospital | Conditions: Glioblastoma | Phase 1 | Status: COMPLETED